Gastric Cancer
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Inclusion Criteria: 1.Age >= 18 years, gender unrestricted. 2. Pathologically confirmed gastric adenocarcinoma via gastroscopic biopsy, staged as TNM Stage ?–? per the 8th edition of the AJCC Gastric Cancer Staging System. 3. Scheduled to receive neoadjuvant chemotherapy combined with immunotherapy (chemotherapy regimens: SOX/XELOX; immunotherapy: PD-1 inhibitor), with no prior antitumor treatment (including chemotherapy, radiotherapy, immunotherapy, etc.). 4.Estimated survival time >= 6 months and Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0–1. 5.Willing to enroll, sign the Informed Consent Form (ICF), and commit to completing 3-month follow-up and sample collection as required.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: 1.Concomitant other active malignancies, or severe cardio-cerebrovascular diseases (e.g., myocardial infarction within the past 6 months, uncontrolled hypertension/uncontrolled diabetes mellitus). 2.History of autoimmune disease, active infection (e.g., active HBV/HCV infection, HIV-positive status), or immunodeficiency. 3.Hypersensitivity to components of chemotherapeutic agents (e.g., oxaliplatin, tegafur–gimeracil–oteracil potassium) or immune checkpoint inhibitors. 4.Administration of immunomodulators (e.g., systemic glucocorticoids at a prednisone-equivalent dose > 10 mg/day) within 3 months prior to enrollment. 5.Unable to comply with sample collection (e.g., contraindications to gastroscopic biopsy) or follow-up (e.g., cognitive impairment).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment Sensitivity; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall Survival (OS); | — |
Countries
China
Contacts
Shanghai General Hospital,Shanghai Jiao Tong University School of Medicine/Shanghai General Hospital